Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Proven Techniques for Reining In Supply Chain Costs

Proven Techniques for Reining In Supply Chain Costs Healthcare delivery in the United States is experiencing a period of extreme flux and uncertainty that is combining to escalate costs. It is compounded by a healthcare supply chain which is vast, complex and plagued with inefficiencies. Supply costs can account for 25-30% of a hospital’s operating…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Proven Techniques for Reining In Supply Chain Costs

Healthcare delivery in the United States is experiencing a period of extreme flux and uncertainty that is combining to escalate costs. It is compounded by a healthcare supply chain which is vast, complex and plagued with inefficiencies. Supply costs can account for 25-30% of a hospital’s operating budget. Supplies relate directly to the patient experience, making it difficult to always settle for the least expensive option. Consequently, hospitals are continually faced with the challenge of decreasing supply chain costs without compromising patient care.

Supply Chain and Physician Preference Items

The balance of cost and function may be most true with Physician Preference Items (PPI) that can account for up to 60% of supply spend. As individual physicians typically select those specific tools with which they are most comfortable, PPI products can be extremely varied across the hospital. This variance, coupled with the high cost of PPI products, makes it difficult for hospital administrators to reduce spend across their organization. In order to keep supply spend in check, healthcare administrators must work collaboratively with physicians and their established preferences to address the financial bottom line and efforts to reduce costs while also improving efficiencies. It’s a collective approach among all stakeholders to balance cost, quality and outcomes.

One opportunity to significantly reduce supply chain inefficiencies and costs is through product standardization. By eliminating the number of similar products, hospitals are able to negotiate more aggressively with vendors to achieve higher value. When it comes to PPI, consideration should be made to determine which items are “preference” driven versus clinically necessary.

Standardizing physician preference items requires involving physicians in the process and educating them with clinical and financial data of clinical utilization patterns, patient outcomes, and product costs and value. While a complex and involved process, the savings extracted from a strategic focus on PPI is well worth the time and investment. TPC is a proven leader in assessing PPI opportunities, collaborating with physicians, and developing successful PPI programs that reduce supply spend without compromising clinical quality or patient care.

TPC Focus on Supply Chain and Physician Preference Items

The TPC model enables hospitals to aggregate their volume to wield increased purchasing power. By drawing upon the combined expertise of Members, TPC gives physicians, nurses, pharmacists and other clinical specialists a method to evaluate products and assess their financial value, as well as their impact on the quality of care. We have found a niche in custom contracting for high-value, complex PPI categories, such as spine and cardiology. By initiating conversations with physicians early in the process we can more effectively evaluate and analyze differences across products and vendors.

TPC collaborates with Members to create a better understanding of the market landscape and drive better decision making. Together, we level-set technology across multiple manufacturers in complex categories and drive standardization in pricing. TPC works with Clinical Value Analysis Teams (CVATs) and Physician Sub-Committees (PSCs) comprised of clinical leaders from each Member facility. These groups offer functionally equivalent, cost-effective solutions to promote a culture of clinical excellence and financial stewardship for all TPC Members. Functional equivalence is determined by objective review of the product using specific, predetermined criteria, and not based on clinical or operational preference. The members of CVATs and PSCs are of vital importance as they serve as clinical advisors, initiative champions and provide clinical input into product decisions.

Through TPC’s custom contracts, Members have achieved significant savings in multiple product categories including, $3.45 million in Cardiac Rhythm Management, $3.5 million in Spinal Implants, and $1.6 million in Interventional Cardiology. As healthcare systems across the country are seeking ways to generate cost savings in the complex category of supply chain, the TPC collaborative model has proven results in reducing supply chain expenses, especially in the challenging area of PPI.

Stronger Together. Superior Results. To learn more about TPC services for supply chain savings, visit http://www.tpc1.com/supply-chain/ today!

Read more at tpc1.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512